![]() ![]() The structure of neuromuscular (NMR) system is influenced by NMR disorders. The arrangement of human neuromuscular structure in human anatomy is a complex aggregation of muscular and nervous system. The work materializes the significance of conventional and deep neural network using time and time-frequency features in diagnosing the abnormal signals exists in neuromuscular system using efficient classification. Correspondingly, the developed conventional single layer artificial neural network ( ) with time domain features has shown an accuracy of 83.3%, sensitivity of 100%, and specificity of 71.42%. Results demonstrate that the deep neural network modelled with layers 2 and 3 ( and 4) using time domain features is efficient in classifying the abnormalities of EMG signals with an accuracy, sensitivity, and specificity of 100% and also exhibited finer performance. The performance of deep neural network exerting selected features from bat algorithm was compared with conventional artificial neural network. Extensively, deep neural network classifier is modelled for selected feature subset using bat algorithm from extracted time and time-frequency features. The selection of substantial characteristics from time and time-frequency features was performed using bat algorithm. Initially, time domain and Wigner-Ville transformed time-frequency features were extracted from abnormal EMG signals for experiments. Hence, for computer-aided identification of abnormalities, extraction of features, selection of superlative feature subset, and developing an efficient classifier are indispensable. The efficient discrimination of abnormal EMG signals, myopathy and amyotrophic lateral sclerosis, engage crucial role in automatic diagnostic assistance tools, since EMG signals are nonstationary signals. BCC, AE, JRB, and MCZ declare that they have no conflicts of interest.Electromyograms (EMG) are a recorded galvanic action of nerves and muscles which assists in diagnosing the disorders associated with muscles and nerves. ![]() ![]() ![]() SV has received the Clive and Vera Ramacciotti grant and the Charles Viertel grant, and has received fees for advisory board from Merck Serono Australia, Novartis Australia, and Biogen (not related to the topic covered in this paper). Funding sources include the National Health and Medical Research Council of Australia (project grants 510243 MCK) the Motor Neurone Disease Research Institute of Australia (MCK) the Irish Health Research Board (OH) American ALS Association (OH) the Irish Motor Neurone Disease Research Foundation (OH) and the Medical Research Council (Lady Edith Wolfson Clinician Scientist Fellowship MRT). She is the inventor of a patent held by the Royal College of Surgeons in Ireland for the use of angiogenin as a therapeutic in ALS. OH has received advisory board fees from Novartis, Biogen, and Merck Sorono, and has received travel and accommodation sponsorship from Merck Sorono. OH has consulted for ONO Pharmaceuticals and KNOPP Pharmaceuticals, and has received research support from Sanofi-Aventis and Serono Pharmaceuticals. In this Seminar, we provide an up-to-date overview of the key developments across the ALS specialty. These collaborative endeavours will inevitably lead to a better understanding of ALS and its often unpredictable progression, and will lead to the development of guidelines for improved care of patients. Furthermore, the power of population registries is being increasingly recognised as an essential adjunct to improved clinical assessment techniques. The development of novel biomarkers to objectively assess disease progression holds the promise of greatly refining therapeutic trial design and reducing trial costs. At present, no definitive diagnostic test or biomarker for ALS exist, and neurologists rely on only clinical criteria for diagnosis. There is a crucial need to formulate therapies that not only slow disease progression, but also deal with the secondary consequences of malnutrition and respiratory failure. The Lancet Regional Health – Western PacificĮxtending life expectancy in ALS seems to be dependent on improving our understanding of its pathogenesis, which will lead to the development of early and specific diagnostic methods.The Lancet Regional Health – Southeast Asia.The Lancet Gastroenterology & Hepatology. ![]()
0 Comments
Leave a Reply. |